after surgery. The intracavernous pressure (ICP) and mean arterial pressure (MAP) was measured and midpenile cross-sections were histologically examined. Western blotting of cavernous tissue protein was performed. The data were analyzed using one-way analysis of variance followed by the Tukey-Kramer t test.
INTRODUCTION AND OBJECTIVES:
To investigate the mechanism of action of pioglitazone (Pio) on the major pelvic ganglion (MPG) and cavernous nerves in a rat model of bilateral cavernosal nerve crush injury (BCNI), to determine a clinically exploitable pathway to treat post-prostatectomy erectile dysfunction.
METHODS: 26 Sprague-Dawley rats weighing 350-400 grams were divided into four groups: (a) sham, (b) BCNI, (c) BCNI þ postsurgical Pio, (d) BCNI þ Pio þ JB-1, an insulin-growth factor-1 (IGF-1) antagonist (JB). Sham and BCNI-only rats were treated with phosphatebuffered saline (PBS), and both Pio and JB rats received 14 days treatment of 6.5 mg Pio per day. PBS and Pio were administered by oral gavage. Sham, BCNI and Pio rats had osmotic mini pumps placed subcutaneously, which delivered saline. JB rats received 100 mg/kg JB-1 trifluoroacetate salt dissolved in saline, delivered by subcutaneous osmotic mini pump. After treatment, animals underwent surgery for endpoint cavernosal response to define hemodynamic parameters of erectile function, reported as the ratio of intracavernosal pressure to mean arterial pressure (ICP/MAP). The MPG and cavernosal nerves were resected at 2 weeks in all rats and processed for Western blot and immunohistochemistry to assess neuronal nitric oxide synthase (nNOS), IGF-1, and ERK 1/2.
RESULTS: Animals treated with Pio after BCNI exhibited improvements in the ICP/MAP ratio, with the Pio group achieving results similar to the sham group. Animals treated with JB-1 in addition to Pio after BCNI achieved results similar to BCNI. At 7.5 V, the ICP/MAP data revealed: sham, 0.627; BCNI, 0.294; Pio, 0.582; JB, 0.286 (P < .05). Both 5V and 2.5 V demonstrated similar results. Western blot and immunohistochemistry results support the surgical data and indicate that Pio 0 s positive effects are mediated by intercellular IGF-1 signaling activity.
CONCLUSIONS: JB-1 reverses the beneficial effects of Pio on erectile function in rats undergoing BCNI, suggesting that Pio acts through IGF-1 signaling pathway. 
The pathophysiology of erectile dysfunction (ED) following radical prostatectomy (RP) was not clearly clarified, and the low efficacy of the major PDE5i treatment remained a frequent complain clinically. This study aimed to demonstrate phenotypic modulation in bilateral cavernous nerve injury (BCNI) rats within 7 days, subsequently verify Myocardin gene therapy to maintain the contractile phenotype of corpus cavernosum smooth muscle cells (CCSMCs).
METHODS: For the first part, 36 male rats were randomly assigned to BCNI and NC groups for histological and molecular measurements at 3, 5, 7 days. Afterwards, a single intracavernosal injection of 50uL PBS, Ad-Myocd (1x10^11 pfu/ml) or Ad-vector was given to three treatment groups with 10 animals each, defined as NCþPBS, BCNIþAd-Myocd, BCNIþvector, at the day of molecular changing day found previously. Finally, the validity and mechanism of Myocardin transfection was explored in vivo and in vitro.
RESULTS: Western blotting revealed canonical declined Myocd, a-SMA, Calponin and elevated OPN expression before corporeal SM-to-collagen ratio and morphological changes at 5th day after modeling. Overexpression of Myocardin maintained the contractile phenotype of CCSMCs, improved BCNI rat intracavernous pressures, as well as suppressed cell proliferative capacity and promoted contractility. In addition, confocal test showed up-regulation and colocalization of serum response factor (SRF) in gene-transfer cells.
CONCLUSIONS: In conclusion, our study was the first to investigate CCSM cell phenotypic switch in the early stage of BCNI rats, and Myocardin was capable of reversing phenotypic modulation by activating SRF. The experimental results validated the efficiency of gene therapy in erectile dysfunction.
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